Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Anemia drug MIRCERA studied in kidney patients before dialysis

NCT ID NCT02567188

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at how well MIRCERA works for anemia in people with chronic kidney disease stages 3-4 who are not yet on dialysis. Researchers tracked 144 patients over 12 months to see if their hemoglobin levels stayed in a healthy range. The goal was to gather real-world data on safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MIRCERA (a drug that stimulates red blood cell production)
What this could lead to
If successful, this study could confirm that MIRCERA helps manage anemia in pre-dialysis kidney disease patients, potentially improving energy and quality of life.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It does not prove MIRCERA is better than other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

144 people

The number who actually took part.

Start date

Apr 2009

Finished

Apr 2011

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participants with CKD Stage 3-4 treated with MIRCERA

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult participants above 18 years of age * Pre-dialysis participants with CKD stage 3-4 treated with MIRCERA and continue in the pre-dialysis state for the whole study period * Estimated glomerular filteration rate (e-GFR) between 15-60 milliliter per minute (mL/min) (calculated) Exclusion Criteria: * Participants involved in interventional trials * Participants with life expectancy less than 1 year * Active malignancy * Planned living kidney transplant within 6 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia chronic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia

Contacts and locations

Locations

  • Study site

    Angeholm, S-262 81, Sweden

  • Study site

    Bollnäs, 821 81, Sweden

  • Study site

    Eskilstuna, 63188, Sweden

  • Study site

    Gävle, 80187, Sweden

  • Study site

    Gothenburg, 41345, Sweden

  • Study site

    Gothenburg, S-402 76, Sweden

  • Study site

    Huddinge, 14186, Sweden

  • Study site

    Jönköping, 55185, Sweden

  • Study site

    Karlshamn, S-374 80, Sweden

  • Study site

    Karlstad, 65185, Sweden

  • Study site

    Kristianstad, 29185, Sweden

  • Study site

    Linköping, S-581 85, Sweden

  • Study site

    Mölndal, S-431 80, Sweden

  • Study site

    Norrköping, 60182, Sweden

  • Study site

    Skövde, 54185, Sweden

  • Study site

    Stockholm, 17176, Sweden

  • Study site

    Stockholm, 18288, Sweden

  • Study site

    Umeå, 90185, Sweden

  • Study site

    Värnamo, 33185, Sweden

  • Study site

    Västervik, 59381, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.